Octagon Capital Advisors

Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Octagon Capital Advisors

Octagon Capital Advisors holds 34 positions in its portfolio as reported in the March 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Nuvation Bio *w Exp 02/10/202 (NUVB.WS) 9.3 $48M +8650% 27M 1.76
 View chart
Apellis Pharmaceuticals (APLS) 8.9 $46M -30% 2.1M 21.87
 View chart
Dianthus Therapeutics (DNTH) 8.2 $43M +10% 2.3M 18.14
 View chart
Arrivent Biopharma (AVBP) 7.4 $38M 2.1M 18.49
 View chart
Centessa Pharmaceuticals Sponsored Ads Put Option (CNTA) 5.6 $29M -5% 2.0M 14.38
 View chart
Trevi Therapeutics (TRVI) 4.0 $21M NEW 3.3M 6.29
 View chart
Gossamer Bio (GOSS) 3.9 $20M 18M 1.10
 View chart
Ocular Therapeutix (OCUL) 3.4 $18M 2.4M 7.33
 View chart
Mind Medicine Mindmed Com New (MNMD) 3.4 $18M 3.0M 5.85
 View chart
Cogent Biosciences (COGT) 3.2 $17M 2.8M 5.99
 View chart
Kalvista Pharmaceuticals (KALV) 3.1 $16M 1.4M 11.54
 View chart
Taysha Gene Therapies Com Shs (TSHA) 2.9 $15M +2% 11M 1.39
 View chart
Nuvation Bio Com Cl A (NUVB) 2.7 $14M -14% 7.9M 1.76
 View chart
Verona Pharma Sponsored Ads (VRNA) 2.7 $14M -61% 217k 63.49
 View chart
Tourmaline Bio (TRML) 2.7 $14M NEW 905k 15.21
 View chart
Merus N V (MRUS) 2.5 $13M 308k 42.09
 View chart
Pharvaris N V (PHVS) 2.3 $12M 770k 15.70
 View chart
Moonlake Immunotherapeutics Class A Ord (MLTX) 2.2 $12M NEW 296k 39.07
 View chart
Syndax Pharmaceuticals (SNDX) 2.1 $11M 904k 12.29
 View chart
Atyr Pharma Com New (ATYR) 2.1 $11M +294% 3.6M 3.02
 View chart
Scholar Rock Hldg Corp (SRRK) 2.0 $11M -32% 329k 32.15
 View chart
Verastem Com New (VSTM) 2.0 $10M NEW 1.7M 6.03
 View chart
Regulus Therapeutics (RGLS) 1.6 $8.1M -4% 4.6M 1.75
 View chart
Silverback Therapeutics (SPRY) 1.5 $7.9M NEW 625k 12.58
 View chart
Abivax Sa Sponsored Ads (ABVX) 1.5 $7.7M NEW 1.2M 6.25
 View chart
Erasca (ERAS) 1.4 $7.0M 5.1M 1.37
 View chart
Miragen Therapeutics (VRDN) 1.2 $6.1M -48% 450k 13.48
 View chart
Corbus Pharmaceuticals Hldgs Com New (CRBP) 1.1 $5.9M 1.1M 5.31
 View chart
Unicycive Therapeutics (UNCY) 1.1 $5.7M 10M 0.57
 View chart
Maze Therapeatics 1.0 $5.2M NEW 468k 11.01
 View chart
Perspective Therapeutics Com New (CATX) 0.9 $4.8M -2% 2.3M 2.13
 View chart
Kalaris Therapeutics 0.7 $3.9M NEW 481k 8.03
 View chart
Neurogene (NGNE) 0.7 $3.5M 303k 11.71
 View chart
Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) 0.5 $2.8M 250k 11.30
 View chart

Past Filings by Octagon Capital Advisors

SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020

View all past filings